Chronic Lymphocytic Leukemia, or CLL, is a type of cancer of the blood and bone marrow characterized by the slow progression of abnormal lymphocytes—a type of white blood cell. While a diagnosis can understandably be frightening, it’s important to understand that CLL often develops slowly, and many people live for years with the condition without needing immediate treatment. Understanding the nuances of chronic lymphocytic leukemia, including available treatment options and the possibility of watchful waiting, is crucial for patients and their families.
CLL is more common in older adults, rarely affecting people under 40. It’s often discovered during a routine blood test before any symptoms appear. Symptoms, when they do occur, can be vague and non-specific, including fatigue, swollen lymph nodes, frequent infections, and unexplained weight loss. Because of this slow progression and potential for asymptomatic presentation, doctors often employ a strategy called “watchful waiting” – also known as observation or active surveillance – particularly in early stages of the disease.
What Does Watchful Waiting Entail?
Watchful waiting, as the name suggests, doesn’t involve immediate intervention with drugs or other therapies. Instead, it’s a period of close monitoring to track the disease’s progression. According to the University of Rochester Medical Center, the goal is to “keep close track of the disease to spot if it gets worse or starts to cause symptoms.” This approach is often favored for individuals with early-stage CLL that isn’t causing significant problems. Research has demonstrated that, in these cases, delaying treatment doesn’t appear to be harmful compared to starting treatment right away.
During watchful waiting, healthcare providers regularly monitor blood counts to identify any changes that might indicate the disease is progressing. They also look for signs of complications, such as recurring infections, rapid swelling of lymph nodes, liver, or spleen, or the development of symptoms like persistent fatigue, fever, or weight loss. Blood draws are a routine part of this monitoring process, allowing doctors to assess how counts change over time – for example, a steadily dropping red blood cell count.
Treatment Options When Intervention Is Needed
When CLL does begin to progress, a variety of treatment options are available. These options have evolved significantly in recent years, offering patients more targeted and effective therapies. The choice of treatment depends on several factors, including the stage of the disease, the patient’s overall health, and the specific characteristics of their CLL.
Targeted Therapy
Targeted therapies are often a first-line recommendation due to their generally milder side effect profiles compared to traditional chemotherapy. These medications function by blocking specific proteins on cancerous cells, disrupting their growth and survival. Several targeted therapies are currently approved for CLL, including acalabrutinib (Calquence), ibrutinib (Imbruvica), idelalisib (Zydelig), pirtobrutinib (Jaypirca), venetoclax (Venclexta), and zanubrutinib (Brukinsa).
Chemotherapy
Chemotherapy involves using strong medications to kill cancer cells. While still a viable option, it’s often reserved for situations where targeted therapies aren’t tolerated or are ineffective, or in cases of more aggressive CLL. Doctors may use a single chemotherapy drug or a combination of them.
Immunotherapy
Immunotherapy harnesses the power of the body’s own immune system to fight cancer. One approach, called chimeric antigen receptor (CAR) T-cell therapy, involves removing immune cells from the patient’s blood, enhancing them in a lab, and then infusing them back into the body to target and destroy leukemia cells. This is typically used when other treatments have failed and can have serious side effects. Another form of immunotherapy uses monoclonal antibodies – laboratory-created proteins that attach to cancer cells, marking them for destruction by the immune system. Rituximab (Rituxan) and obinutuzumab (Gazyva) are examples of monoclonal antibodies used in CLL treatment.
Less Common Treatments
Stem cell transplants, while sometimes used in other leukemias, are uncommon for CLL. Radiation therapy may be used to alleviate pain or as preparation for a stem cell transplant, but is also not a primary treatment. Surgery, generally, isn’t curative for CLL due to its widespread nature, but may be considered if an enlarged spleen is causing complications. In rare cases where a high concentration of CLL cells causes circulation problems, a procedure called leukapheresis can temporarily remove these cells from the blood.
Living with CLL requires ongoing monitoring and collaboration with a healthcare team. While there is currently no cure for most people with CLL, advancements in treatment continue to improve outcomes and quality of life. The landscape of CLL treatment is constantly evolving, with ongoing clinical trials exploring latest therapies and approaches.
The next key development to watch for in CLL research is the continued evaluation of novel targeted therapies and immunotherapies in clinical trials, aiming to refine treatment strategies and improve long-term outcomes for patients. For more information and support, patients are encouraged to connect with organizations like the Leukemia & Lymphoma Society.
Have you or a loved one been affected by CLL? Share your experiences and questions in the comments below.
